iSpecimen Inc.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $6.9M+266.3% | $1.9M-19.9% | $2.3M-84.7% | $15.3M |
| Accounts receivable and other receivables, net of allowance for doubtful accounts of $646,067 and $620,433 at December 31, 2025 and 2024, respectively | $48K-96.7% | $1.4M+98.3% | $728K-54.4% | $1.6M |
| Inventory | $45K | — | — | — |
| Prepaid expenses and other current assets | $25K-88.4% | $220K-24.8% | $292K-2.8% | $300K |
| Total current assets | $7.0M+93.8% | $3.6M-56.4% | $8.2M-58.1% | $19.7M |
| Property and equipment, net | $26K-72.7% | $94K-26.8% | $128K-43.4% | $226K |
| Internally developed software, net | $1.3M-72.5% | $4.6M-27.1% | $6.3M+40.4% | $4.5M |
| Intangible assets under development | $1.0M | — | — | — |
| Other intangible assets, net | $717K | — | $908K | — |
| Operating lease right-of-use asset | $269K-17.9% | $328K+69.2% | $194K+5.0% | $185K |
| Security deposits | $12K+0.0% | $12K-56.2% | $28K+0.0% | $28K |
| Total assets | $9.5M+1.9% | $9.4M-40.9% | $15.8M-35.7% | $24.6M |
| Accounts payable | $5.4M+27.8% | $4.2M+6.9% | $3.9M+59.6% | $2.5M |
| Accrued expenses | $619K-47.0% | $1.2M-24.1% | $1.5M+0.6% | $1.5M |
| Operating lease current obligation | $57K+31.3% | $43K-74.0% | $167K+5.5% | $158K |
| Deferred revenue | $193K-46.6% | $361K-13.2% | $416K+214.2% | $132K |
| Total current liabilities | $6.2M+8.0% | $5.8M-4.6% | $6.0M+41.3% | $4.3M |
| Operating lease long-term obligation | $212K-21.2% | $269K+822.8% | $29K+6.3% | $27K |
| Total liabilities | $6.4M+6.7% | $6.0M-0.6% | $6.1M+41.1% | $4.3M |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 8,480,147 issued and 8,478,597 outstanding at December 31, 2025 and 1,698,454 issued and 1,696,904 outstanding at December 31, 2024 | $848+398.8% | $170+277.8% | $45-95.0% | $892 |
| Additional paid-in capital | $85.4M+13.7% | $75.2M+8.8% | $69.1M+0.8% | $68.6M |
| Treasury stock, 1,550 shares at December 31, 2025 and 2024, at cost | -$172+0.0% | -$172+0.0% | -$172+0.0% | -$172 |
| Accumulated deficit | -$82.4M-14.6% | -$71.9M-21.1% | -$59.4M-23.0% | -$48.3M |
| Total stockholders’ equity | $3.1M-6.7% | $3.3M-66.0% | $9.7M-52.0% | $20.3M |
| Total liabilities and stockholders’ equity | $9.5M+1.9% | $9.4M-40.9% | $15.8M-35.7% | $24.6M |
| Series C Convertible Preferred Stock | ||||
| Series C convertible preferred stock, $0.0001 par value 50,000,000 shares authorized, 6,875 issued and outstanding at December 31, 2025 and Nil issued and outstanding as at December 31, 2024 | $1 | — | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.